A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

Clinical trial NCT06470373 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06470373
Sponsor: Rophibio, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Neovascular Age-related Macular Degeneration (nAMD)

Start date: 2025-07-01
Primary completion: 2026-09-01
Enrollment: 434

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.